Court Rejects J&J Bid For Injunction In Amgen Case

Law360, New York (November 23, 2006, 12:00 AM EST) -- A federal judge in New Jersey has rejected Johnson & Johnson's request for a preliminary injunction against Amgen's marketing practices for anemia drug Aranesp in the ongoing antitrust battle between the two life-sciences giants.

On Wednesday, U.S. District Court Judge Stanley Chesler denied a request from the Johnson & Johnson Inc. biotech unit Ortho Biotech Products to block rebate contracts that encourage doctors to use the anemia treatment Aranesp when they use Neupogen or Neulasta, two Amgen drugs used to prevent infections in chemotherapy patients....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.